The NuPharm Group, created in 2016 is a strategic combination of leading and experienced European pharmaceutical companies with outstanding development, manufacturing and sales capabilities focused on CNS. NuPharm has 680 employees across its five companies neuraxpharm, Qualigen, FB Health, Laboratorios Lesvi and Inke.
Its dedicated sales presence commercializes branded CNS products, INN generics and nutraceuticals in Europe. Additionally, with an international presence in more than 50 countries, the Group also manufactures finished dosage forms (FDFs) and niche active pharmaceutical ingredients (APIs) in the CNS and the respiratory areas.
with sales forces in our main EU markets to strengthen our international position as a leader in CNS
into a robust pipeline that broadens our CNS portfolio with differentiated products
with the European community of CNS patients and healthcare professionals
and optimisation of our international portfolio through B2B selling of FDFs and APIs
via backward integration and strengthening operational excellence within the Group
with a strong focus on quality, collaboration and agility promoting smart solutions that differentiate us from our competitors
NuPharm Group owns and operates three European distribution and marketing companies with a special focus on CNS
Leading CNS generic pharmaceutical company in Germany, specialised in standard and differentiated generics and originals
Specialised in commercialising medicinal products in Spain with a strategic approach to products for CNS disorders
One of the top-selling specialty generic players in Italy with a focus on CNS drugs and nutraceuticals
NuPharm Group also owns and operates two manufacturing plants in Spain
High international presence through selling APIs and FDFs to more than 50 countries